Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences (Nasdaq: ALIM) is a leader in developing sustained-release therapies for retinal diseases like diabetic macular edema. This page provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and financial performance.
Access consolidated news about ALIM’s ophthalmic innovations, including updates on its flagship products ILUVIEN® and YUTIQ®. Track progress in clinical trials, partnership announcements, and market expansion efforts across global regions.
Key updates include earnings reports, FDA/EMA regulatory actions, research publications, and strategic initiatives. Our curated news collection ensures you stay informed about developments impacting ALIM’s position in the ophthalmic pharmaceutical sector.
Bookmark this page for streamlined access to Alimera Sciences’ official communications and third-party analyses. Check regularly for objective updates supporting informed decisions about this innovative healthcare company.
Alimera Sciences (Nasdaq: ALIM) has filed a lawsuit against ANI Pharmaceuticals (Nasdaq: ANIP) in the Delaware Court of Chancery to enforce the previously announced merger agreement. The legal action aims to compel ANI to close the merger transaction and honor its contractual obligations. Alimera shareholders approved the merger on September 4, fulfilling the last requirement for closing. The company states that it has met all its obligations, but ANI has failed to close on time. Alimera believes the merger offers compelling value for shareholders and is committed to completing the transaction. The lawsuit specifically requests the Court to require ANI to comply with its obligations to finalize the merger as outlined in the Agreement and Plan of Merger dated June 21, 2024.
Alimera Sciences reported strong Q2 2024 results with net revenue up 54% to $27 million compared to Q2 2023. Key highlights include:
- U.S. net revenue increased 48% to $17.6 million
- International net revenue grew 65% to $9.4 million
- Global end user demand up 6% to 3,821 units
- Net loss improved to $(3.3) million from $(10.7) million in Q2 2023
- Adjusted EBITDA of $6.7 million vs. $0.9 million in Q2 2023
The company recently announced a definitive merger agreement with ANI Pharmaceuticals, valuing Alimera's equity at approximately $320 million in upfront consideration. The transaction is expected to close later this year.
Alimera Sciences announced inducement awards under Nasdaq Listing Rule 5635(c)(4) linked to the recruitment of five non-executive employees. Approved on May 22, 2024, the awards grant options to purchase 64,000 shares of common stock at $3.00 per share. These options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the next 36 months. The awards are part of Alimera's 2024 Equity Inducement Plan and are designed to attract new talent.
Alimera Sciences reported a 70% increase in net revenue, reaching $23 million in Q1 2024, compared to $13.5 million in Q1 2023. U.S. net revenue surged 92% to $14.6 million, while international revenue grew 42% to $8.5 million. Despite a net loss of $6.3 million, Alimera achieved a positive adjusted EBITDA of $1.8 million. Key milestones include the completion of enrollment in the Synchronicity Study and NICE’s recommendation for ILUVIEN access in the UK. However, total operating expenses rose to $22 million, driven by sales, marketing, and amortization costs.
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the presentation of three scientific abstracts at upcoming ophthalmic congresses. The abstracts will focus on safety outcomes and retinal thickness related to the 0.18 mg Fluocinolone Acetonide Intravitreal Implant in patients with Chronic Non-infectious Uveitis. The conferences include the ARVO and RWC, showcasing research by renowned physicians in the field.
Alimera Sciences, a global pharmaceutical company, will report its first quarter 2024 financial results on May 14, 2024, and hold a conference call at 9:00 AM ET on the same day to discuss financial performance and corporate updates. Participants can register for the conference call online or dial-in directly. A webcast replay will be available after the call.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
